Dermapharm Holding SE (ETR:DMP)
Market Cap | 2.12B |
Revenue (ttm) | 1.17B |
Net Income (ttm) | 90.59M |
Shares Out | 53.84M |
EPS (ttm) | 1.68 |
PE Ratio | 23.44 |
Forward PE | 17.18 |
Dividend | 0.88 (2.27%) |
Ex-Dividend Date | Jun 28, 2024 |
Volume | 1,050 |
Average Volume | 16,779 |
Open | 39.35 |
Previous Close | 38.60 |
Day's Range | 38.45 - 39.40 |
52-Week Range | 30.15 - 41.85 |
Beta | 1.08 |
RSI | 52.38 |
Earnings Date | Mar 14, 2025 |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain a... [Read more]
Financial Performance
In 2023, Dermapharm Holding SE's revenue was 1.15 billion, an increase of 10.59% compared to the previous year's 1.04 billion. Earnings were 62.37 million, a decrease of -53.54%.
Financial StatementsNews

EQS-DD: Dermapharm Holding SE: Wilhelm Beier, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 30.12.2024 / 12:38 CET/CEST The issuer is solely responsi...

EQS-DD: Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 11.11.2024 / 16:30 CET/CEST The issuer is solely responsi...

EQS-DD: Dermapharm Holding SE: Christof Dreibholz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.11.2024 / 15:12 CET/CEST The issuer is solely responsi...

Dermapharm Holding SE: High-Margin Pharma Boosts Global Organic Growth
Dermapharm Holding SE showcases robust organic growth in its branded pharmaceuticals segment, offsetting a revenue dip from the cessation of pandemic-related vaccine production. Unadjusted EBITDA surg...

EQS-News: Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies
EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at Germa...

Dermapharm Holding: Thriving on High-Margin Organic Growth in Pharma Business
Despite a slight dip in overall revenue and earnings, strong performance in branded pharmaceuticals has helped Dermapharm navigate the post-pandemic landscape. The company remains optimistic about its...

EQS-News: Sustained organic growth in high-margin existing branded pharmaceutical business
EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Sustained organic growth in high-margin existing branded pharmaceutical business 14.08.2024 / 07:30 CET/CEST The is...